{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-010030","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.734552+00:00","generated_at":"2026-05-15T08:39:00.552344+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Monopar Q4 net loss $5.2M, cash $140.4M; ALXN1840 NDA planned mid-2026","bullets":["Q4 2025 net loss $5.2M ($0.61/sh) vs $10.9M ($2.23) YoY; full-year net loss $13.7M ($1.85/sh) vs $15.6M.","Cash, equivalents and short-term investments $140.4M at Dec 31, 2025, expected to fund operations through Dec 31, 2027.","NDA submission for ALXN1840 (Wilson disease) planned mid-2026; abstracts accepted at EASL 2026 and AAN 2026.","Completed underwritten public offering generating ~$91.9M after concurrent stock repurchase in 2025.","Appointed Susan Rodriguez as Chief Commercial and Strategy Officer for potential ALXN1840 launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-010030","json":"https://secwatch.observer/filing/0001437749-26-010030.json","markdown":"https://secwatch.observer/filing/0001437749-26-010030.md","text":"https://secwatch.observer/filing/0001437749-26-010030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926010030/0001437749-26-010030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926010030/mnpr20260326_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:39:00.552344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c45fef80bdc33d7a6a8020c1417775d562fc4f0","claim":"Monopar Therapeutics reported year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025, was $13.7 million, or $1.85 per share.","evidence_excerpt":"Net loss for the year ended December 31, 2025, was $13.7 million, or $1.85 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926010030/0001437749-26-010030-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2025"},{"label":"Net income","value":"Net loss for the year ended December 31, 2025, was $13.7 million, or $1.85 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"5ba65dab28745e39f0482ad2a0fe594e31c0edce","claim":"Monopar Therapeutics reported fourth quarter and full year ended December 31, 2025 results: net income Net loss for the fourth quarter of 2025 was $5.2 million, or $0.61 per share.","evidence_excerpt":"the fourth quarter and full-year 2025 financial results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926010030/0001437749-26-010030-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2025"},{"label":"Net income","value":"Net loss for the fourth quarter of 2025 was $5.2 million, or $0.61 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}